



New Therapeutic and Management Strategies for Childhood Cancers

Guest Editor:

Dr. Saurabh Agarwal

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY 11439, USA

Deadline for manuscript submissions:

closed (31 March 2023)

Message from the Guest Editor

In this Special Issue of *Current Oncology*, we invite authors to contribute original research and review articles focusing on different aspects of childhood or pediatric cancer development, causes, maintenance, and therapeutic strategies. We will also consider articles on developmental targeted therapeutic approaches pertaining to any childhood cancer including but not limited to acute lymphoblastic leukemia, acute myeloid leukemia, astrocytoma, oligodendroglioma, ependymoma, choroid plexus carcinoma, oligoastrocytoma, glioblastoma, ganglioglioma, desmoplastic infantile ganglioglioma, anaplastic ganglioglioma, gangliocytoma, medulloblastoma, rhabdomyosarcoma, pineocytoma, osteosarcoma, Ewing sarcoma, neuroblastoma, Wilms tumors, retinoblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, hepatoblastoma, and hepatocellular carcinoma. The collected articles in this Special Issue will further enhance our knowledge and understanding of childhood cancers and drive the development of novel therapeutic and management strategies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.**

Journal Rank: JCR - Q2 (*Oncology*)

Contact Us

Current Oncology Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/currnocol
currentoncology@mdpi.com
[X@CurrentOncology](https://twitter.com/CurrentOncology)